Developing Drug against COVID-19

1. Developing Drug against COVID-19

2. A New Class of Antiviral Drug
for COVID-19
 The novel coronavirus COVID-19 respiratory disease, has infected
over 11 million people, killed over 0.5 million in the first six months
of the current pandemic
 Scientists around the world are racing against time to find a cure.
 Researchers are also testing older medications.
 Vaccines are under initial development, but final results are difficult
to predict.
 Currently, there are no FDA approved antiviral drugs for the
treatment of human coronavirus infections.
 “We need an oral antiviral agent which could be given during very
early stage of infection. It should completely cure the patient. The
antiviral agents currently in the clinical trials, do not meet these
criteria.” - Dr. Fauci
AntiRNA

3. The Technical Objectives
 Antiviral agents interfering in S-adenosylmethionine
(SAM)-dependent methylation reactions are potent
antiviral agents.
 Scientists and Pharmaceutical companies are
attempting to repurpose known drugs.
 None of the “repurpose” drugs are very effective and
prevent RNA methylation.
AntiRNA

4. Innovation
AntiRNA
 We plan to develop broad spectrum antiviral agents
interfering RNA methylation process to treat COVID-
19 infection (Patent Pending)
 We have previously developed potent antiviral
agents which interfere with S-adenosylmethionine
(SAM)-dependent methylation reactions, particularly
those involved in the ‘capping’ of viral mRNA.

5. The Technical Approach
AntiRNA
Phase 1 Tasks
 Synthesize first prototype nucleoside derived antiviral agent and
obtain in vitro and in vivo data.
 Analyze the collected data and establish the effectiveness of
molecule in prevention of infection and viral replication in the
COVID-19 infected cells.
Phase 2 Tasks
 Synthesize derivatives of parent molecule with variable functional
group and get all of them tested for viral infection and replication.
Use orthogonal assay method for testing and analyze data on
matrix parameter.
 Perform GLP manufacturing and IND assessment.

6. Target and Market
Opportunity
 Remdesivir, a repurpose drug further along in the Clinical
trails is only partially effective in some patients at the early
stage of infection.
 The estimated revenue of Remdesivir could be in excess of
$2B, according to the Institute for Clinical and Economic
Review recommended for a 10-day treatment.
 Worldwide sale could easily be in the range of $7B revenue
annually.
 An anti-viral drug treating COVID-19 infected patients
should generate about the same revenue and market
potential.
AntiRNA

7. Alliance and Revenue
Opportunity
 Small biotechnology companies rely heavily on strategic
alliances with larger pharmaceutical companies to market
their drugs.
 The larger well-established pharmaceutical companies
have resources and network to market the innovative
drugs which have potentially larger market share.
 Considering the potential market of a new anti-viral drug
to treat COVID-19, we should be able to establish
alliances with larger pharmaceutical companies after
obtaining initial biological data.
AntiRNA

8. Team
Suhaib Siddiqi, Ph.D., Founder and CEO,
 Dr. Siddiqi has over 40 years’ experience in Nucleic Acids and anti-viral drugs’
research and development.
 Invented “Virtual Terminators” for DNA Single Molecule Sequencing.
 Discoverer of a potent, non-toxic broad-spectrum anti-viral agent.
 Held leadership and executive positions at various biotechnology and pharmaceutical
companies.
 Has 31 peer-reviewed publications and 42 US and International patents.
Rizwan Manzer, MD, MBA, Co-Founder and SVP Research and Development, Dr.
Manzer has more than 2 decades of combined experience of research and development in
academic and industrial settings. He has invested a substantial part of his research career
to study the innate immunity against pathogens in the lungs. He discovered the origin of
CXCL5(LIX) in the lung. Dr. Manzer has published 12 original articles in the peer-
reviewed journals and has been in CMC and technical operation roles for several
biotechnology and pharmaceutical companies.
AntiRNA

9. Financials
AntiRNA
ROM (Rough Order of Magnitude Estimates) and Schedule:
Phase 1 - ROM $508,000, POP 4 months
Exit criteria: Synthesize (-)5’-Nor-aristeromycin and obtain in vitro biological test
data as antiviral agent against COVID-19.
Phase 2 - ROM $640,000, POP 8 months
Exit criteria:
 Obtain in vivo data for (-)5’-Nor-aristeromycin
 Synthesize derivatives of (-)5’-Nor-aristeromycin for SAR development.
Total POP: 12 months; Total Costs: $1,188,000
Products and Deliverable:
Phase 1: Requirement: Synthesis of (-)5’-Nor-aristeromycin and proof of concept
by through in vitro testing.
Phase 2: in vivo data; prototype antiviral drug ready for IND, out-licensing and
alliances building.

10. Contact Us
For Executive Summary and
discussions, please contact us.
AntiRNA